fig1
Figure 1. ROS1 pathway and resistance mechanism.Molecular mechanisms of ROS1 Inhibitors in ROS-1 rearranged lung cancer patients. Molecular pathways to resistance include an activated ROS1 kinase which activates the SHP-2 phosphatase and increases the JAK/STAT3, PI3K/AKT/mTOR, RAS/RA/MEK/ERK signaling pathways to promote growth and survival of the cell.
